The CDSCO Panel rejects Nacto Pharma's request for a waiver of the Phase III CT for the anticancer erefitinib tablet.

Published Date: 14 Aug 2023

New Delhi: The Subject Expert Committee (SEC) has rejected the waiver of the proposed Phase III clinical trial for the dosages of 3 mg, 4 mg, and 5 mg of erlotinib tablets.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot